Antidiabetic actions of an estrogen receptor β selective agonist

Diabetes

Volumn 62, Issue 6, 2013, Pages 2015-2025

  Alonso Magdalena, Paloma ^a   Ropero, Ana B ^a   García Arévalo, Marta ^a   Soriano, Sergi ^a   Quesada, Iván ^a   Muhammed, Sarheed J ^b   Salehi, Albert ^b   Gustafsson, Jan Ake ^c,d   Nadal, Ángel ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b LUND UNIVERSITY   (Sweden)

^c University of Houston   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIDIABETIC AGENT; ESTROGEN RECEPTOR BETA; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; WAY 200070;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR BETA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; NIACINAMIDE; OXAZOLES; PHENOLS; STREPTOZOCIN;

EID: 84878237251     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1562     Document Type: Article

References (47)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2011;8:228-236
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
3. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009;52:1003-1012
4. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812 (Pubitemid 44033300)
5. Weir GC, Marselli L, Marchetti P, Katsuta H, Jung MH, Bonner-Weir S. Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab 2009;11(Suppl. 4):82-90
6. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-2162
7. Tharakan G, Tan T, Bloom S. Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 2011;32:8-15
8. Gallwitz B, Häring HU. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2010;12:1-11
9. Pearson ER. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Front Biosci 2009;14:4348-4362
10. Alonso-Magdalena P, Ropero AB, Carrera MP, et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS ONE 2008;3: e2069
11. Soriano S, Ropero AB, Alonso-Magdalena P, et al. Rapid regulation of K(ATP) channel activity by 17beta-estradiol in pancreatic beta-cells involves the estrogen receptor beta and the atrial natriuretic peptide receptor. Mol Endocrinol 2009;23:1973-1982
12. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011;10:778-792
13. Sugiyama N, Barros RP, Warner M, Gustafsson JA. ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab 2010;21:545-552
14. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11:597 -608
15. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998;95:15677-15682 (Pubitemid 29018759)
16. Tahara A, Matsuyama-Yokono A, Shibasaki M. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol 2011;655:108-116
17. Matsuyama-Yokono A, Tahara A, Nakano R, et al. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin- nicotinamide- induced mildly diabetic mice. Metabolism 2009;58:379-386
18. Nadal A, Rovira JM, Laribi O, et al. Rapid insulinotropic effect of 17betaestradiol via a plasma membrane receptor. FASEB J 1998;12:1341-1348 (Pubitemid 28475575)
19. Valdeolmillos M, Nadal A, Contreras D, Soria B. The relationship between glucose-induced K+ATP channel closure and the rise in [Ca2+]i in single mouse pancreatic beta-cells. J Physiol 1992;455:173-186
20. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006;39:155 -162
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248 -254
22. Soriano S, Alonso-Magdalena P, García-Arévalo M, et al. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor β. PLoS ONE 2012;7:e31109
23. Barros RP, Gustafsson JA. Estrogen receptors and the metabolic network. Cell Metab 2011;14:289 -299
24. Nadal A, Alonso-Magdalena P, Soriano S, Quesada I, Ropero AB. The pancreatic beta-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Mol Cell Endocrinol 2009;304:63-68
25. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012;61:145-154
26. Musatov S, Chen W, Pfaff DW, et al. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:2501 -2506
27. Liang YQ, Akishita M, Kim S, et al. Estrogen receptor beta is involved in the anorectic action of estrogen. Int J Obes Relat Metab Disord 2002;26:1103-1109
28. Bryzgalova G, Gao H, Ahren B, et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 2006;49:588-597 (Pubitemid 43277883)
29. Lundholm L, Bryzgalova G, Gao H, et al. The estrogen receptor alpha-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ ob mice; potential molecular mechanisms. J Endocrinol 2008;199:275-286
30. Barros RP, Machado UF, Warner M, Gustafsson JA. Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci U S A 2006;103:1605-1608 (Pubitemid 43192077)
31. Yepuru M, Eswaraka J, Kearbey JD, et al. Estrogen receptor-beta-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem 2010;285:31292-31303
32. Kumar R, Balhuizen A, Amisten S, Lundquist I, Salehi A. Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 2011;152:2568-2579
33. Balhuizen A, Kumar R, Amisten S, Lundquist I, Salehi A. Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol 2010;320:16-24
34. Sharma G, Prossnitz ER. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 2011;152:3030-3039
35. Liu S, Le May C, Wong WP, et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009;58:2292-2302
36. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF Jr. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci U S A 1977;74:2485-2489
37. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M. Hypoglycaemic effects of antidiabetic drugs in streptozotocin- nicotinamideinduced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic Clin Pharmacol Toxicol 2008;103:560-568
38. Yamabe N, Kang KS, Zhu BT. Beneficial effect of 17β-estradiol on hyperglycemia and islet β-cell functions in a streptozotocin-induced diabetic rat model. Toxicol Appl Pharmacol 2010;249:76-85
39. Goodman MN, Hazelwood RL. Short-term effects of oestradiol benzoate in normal, hypophysectomized and alloxan-diabetic male rats. J Endocrinol 1974;62:439-449
40. Tiano JP, Delghingaro-Augusto V, Le May C, et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. J Clin Invest 2011;121:3331-3342
41. Choi SB, Jang JS, Park S. Estrogen and exercise may enhance beta-cell function and mass via insulin receptor substrate 2 induction in ovariectomized diabetic rats. Endocrinology 2005;146:4786-4794
42. Fu Z, Zhang W, Zhen W, et al. Genistein induces pancreatic beta-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinology 2010;151:3026-3037
43. Mellado-Gil JM, Cobo-Vuilleumier N, Gauthier BR. Islet β-Cell mass preservation and regeneration in diabetes mellitus: four factors with potential therapeutic interest. J Transplant 2012;2012:230870
44. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824-5829 (Pubitemid 33152630)
45. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002;51(Suppl. 1):S117-S121 (Pubitemid 34761505)
46. Barros RP, Gabbi C, Morani A, Warner M, Gustafsson JA. Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. Am J Physiol Endocrinol Metab 2009;297:E124-E133
47. Foryst-Ludwig A, Clemenz M, Hohmann S, et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genet 2008;4:e1000108